The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 WEN Tianfu , LI Chuan , ZHANG Xiaoyun , PENG Wei , SHEN Junyi

Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

WEN Tianfu, Email: wentianfu@scu.edu.cn

Keywords：

liver cancer; conversion to resectability; screening; HBV infection; MDT

DOI：

10.7507/1007-9424.202308033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

To challenge the 15% enhancement of 5-year survival of cancer for the plan of “Health-China 2030”, we must strive the following measurements to complete the 15% enhancement of 5-year survival of liver cancer: conduct conversion therapy and conversion to resectability for the 70% of unresectable intermediate-to-advanced stage liver cancer so as to prolong survival; try our best to identify and treat the people of HBV and HCV infection, and to screen the risk people so as to reduce the incidence of liver cancer and the proportion for intermediate-to-advanced stage liver cancer; continue to try our best in the full course management of liver cancer under the frame of MDT.

Citation： WEN Tianfu, LI Chuan, ZHANG Xiaoyun, PENG Wei, SHEN Junyi. The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(11): 1281-1283. doi: 10.7507/1007-9424.202308033 Copy

1.	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	International Agency for Research on Cancer. Data visualization tools for exploring the global cancer burden in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
4.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
5.	《“健康中国2030”规划纲要》 (附全文). https://www.sohu.com/a/275717094_727248.
6.	Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival. Surgery, 1970, 68(2): 383-388.
7.	Yu YQ, Tang ZY, Zhou XD, et al. Treatment of huge primary liver cancer in stages. Chin J Surg, 1983, 21: 92-93.
8.	Chen H, Wu MC. Reoperative primary liver cancer. Report of 28 cases. Chin Med J (Engl), 1987, 100(10): 795-799.
9.	Sitzmann JV, Order SE, Klein JL, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol, 1987, 5(10): 1566-1573.
10.	Tang ZY, Yu YQ, Ma ZC, et al. Conversion of surgically verified unresectable to resectable hepatocellular carcinoma-a report of 26 patients with subsequent resection. Chinese J Cancer Res, 1989, 1: 41-47.
11.	Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg, 2004, 240(2): 299-305.
12.	文天夫. 转化切除是提高肝细胞癌切除率的重要途径. 中国普外基础与临床杂志, 2020, 27(2): 133-136.
13.	He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
14.	Zhang XY, Zhu XR, Li C. The safety and efficacy of TACE+lenvatinib+PD-1 antibody of advanced unresectable HCC. 2022 ASCO-GI, poster session 45, San Francisco, California, United States.
15.	张晓赟, 朱心睿, 彭伟, 等. 经肝动脉化疗栓塞+仑伐替尼+PD-1单抗在中晚期不可切除肝癌转化切除中的安全性和有效性的前瞻性队列研究: 初步报告. 中国普外基础与临床杂志, 2022, 29(1): 39-45.
16.	Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
17.	Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther, 2023, 8(1): 58. doi: 10.1038/s41392-022-01235-0.
18.	Peng W, Zhang X, Li C, et al. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg, 2023, 110(7): 746-748.
19.	Zhang XY, Zhu X, Feng X, et al. The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study. Ann Oncol, 2022, 33: Issue S7-s870-715p.
20.	张晓赟, 朱心睿, 彭伟等. 仑伐替尼+经肝动脉化疗栓塞+PD-1单抗治疗肝细胞癌合并门静脉主干癌栓和海绵样变 (4例报道). 中国普外基础与临床杂志, 2022, 29(5): 618-622.
21.	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019年版). 中国实用外科杂志, 2020, 40(2): 121-138.
22.	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南 (2022年版). 中华肝脏病杂志, 2022, 30(12): 1309-1331.
23.	四川大学华西医院肝癌MDT团队. 肝细胞癌切除术后复发转移的防治: 华西医院多学科专家共识. 中国普外基础与临床杂志, 2017, 24(8): 927-939.
24.	Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
25.	樊嘉. 我国肝癌诊疗和临床研究进展. 中国实用外科杂志, 2019, 39(10): 1010-1014.

1. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. International Agency for Research on Cancer. Data visualization tools for exploring the global cancer burden in 2020. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
4. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
5. 《“健康中国2030”规划纲要》 (附全文). https://www.sohu.com/a/275717094_727248.
6. Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival. Surgery, 1970, 68(2): 383-388.
7. Yu YQ, Tang ZY, Zhou XD, et al. Treatment of huge primary liver cancer in stages. Chin J Surg, 1983, 21: 92-93.
8. Chen H, Wu MC. Reoperative primary liver cancer. Report of 28 cases. Chin Med J (Engl), 1987, 100(10): 795-799.
9. Sitzmann JV, Order SE, Klein JL, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol, 1987, 5(10): 1566-1573.
10. Tang ZY, Yu YQ, Ma ZC, et al. Conversion of surgically verified unresectable to resectable hepatocellular carcinoma-a report of 26 patients with subsequent resection. Chinese J Cancer Res, 1989, 1: 41-47.
11. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg, 2004, 240(2): 299-305.
12. 文天夫. 转化切除是提高肝细胞癌切除率的重要途径. 中国普外基础与临床杂志, 2020, 27(2): 133-136.
13. He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
14. Zhang XY, Zhu XR, Li C. The safety and efficacy of TACE+lenvatinib+PD-1 antibody of advanced unresectable HCC. 2022 ASCO-GI, poster session 45, San Francisco, California, United States.
15. 张晓赟, 朱心睿, 彭伟, 等. 经肝动脉化疗栓塞+仑伐替尼+PD-1单抗在中晚期不可切除肝癌转化切除中的安全性和有效性的前瞻性队列研究: 初步报告. 中国普外基础与临床杂志, 2022, 29(1): 39-45.
16. Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
17. Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther, 2023, 8(1): 58. doi: 10.1038/s41392-022-01235-0.
18. Peng W, Zhang X, Li C, et al. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg, 2023, 110(7): 746-748.
19. Zhang XY, Zhu X, Feng X, et al. The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study. Ann Oncol, 2022, 33: Issue S7-s870-715p.
20. 张晓赟, 朱心睿, 彭伟等. 仑伐替尼+经肝动脉化疗栓塞+PD-1单抗治疗肝细胞癌合并门静脉主干癌栓和海绵样变 (4例报道). 中国普外基础与临床杂志, 2022, 29(5): 618-622.
21. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019年版). 中国实用外科杂志, 2020, 40(2): 121-138.
22. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南 (2022年版). 中华肝脏病杂志, 2022, 30(12): 1309-1331.
23. 四川大学华西医院肝癌MDT团队. 肝细胞癌切除术后复发转移的防治: 华西医院多学科专家共识. 中国普外基础与临床杂志, 2017, 24(8): 927-939.
24. Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
25. 樊嘉. 我国肝癌诊疗和临床研究进展. 中国实用外科杂志, 2019, 39(10): 1010-1014.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The key to 15% enhancement of 5-year survival for liver cancer for the plan of “Health-China 2030”

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content